Posted by Michael Wonder on 27 Sep 2018
Aronora's new blood clot treatment receives FDA fast track designation
26 September 2018 - Enzyme that selectively targets blood clots has received FDA fast track designation, allowing for expedited clinical development.
Aronora today announced that the U.S. FDA has granted fast track designation for proCase (E-WE thrombin, AB002), an enzyme that is intended to reverse blood clot formation without increasing the risk of bleeding.
Despite currently approved treatments, over one million people still die from blood clots every year in the U.S.
